Amarantus Bioscience Holdings Inc (AMBS)

[Riskreturn168]

Let's Do Some Dot Connecting. (Speculation) GDNF was first brought forward by Joseph Rubenfield's company AMGEN. After they put a stop to their Phase 2 study, AMGEN licensed it to Medgenesis. Is it possible that the Phase 2b drug that AMBS licensed earlier this year...is GDNF? I know, I know, it's crazy. But, Joseph Rubenfield is the connection between the two drugs: GDNF and MANF. And, Maeve Caldwell of the University of Bristol in England has done tests combining the big three PD drugs: GDNF, CDNF (Mart Saarma's drug), and MANF. She showed that MANF and CDNF were superior to GDNF, but that the best results were found when combining CDNF WITH MANF! (My son found a video lecture by her on Youtube, explaining this) What if our own Rubenfield, in an effort to salvage GDNF, came up with the idea that by combining it with MANF in a Phase 2 study, along with a superior delivery mechanism (Renshaw), that maybe this new combination would do the trick to solve the LID issues associated with Parkinsons treatments?

Is it possible that the FDA might allow MANF, once it submits its IND next year for Parkinsons, to skip a Phase 1 study and be used jointly with GDNF in some kind of "cocktail?" Since a Phase 1 is mostly about the toxicity of drugs in humans, and since GDNF and MANF are natural drugs, and since MANF is very similar to GDNF...might the FDA allow MANF to get into a Phase 2 trial with GDNF in late 2014 or early 2015?

If Medgenesis hasn't thought of this...maybe they should. Why should they spend over 100 million on GDNF when MANF has been shown to be superior? By joining them...both companies benefit.